White House changes course to kill rebate reform
So what exactly is the White House’s plan to tackle rising drug prices? It doesn’t look like we will get definitive answers anytime soon. On the heels of President Donald Trump’s surprise revelation that an executive order is in the works to implement a “favored nations clause,” his administration is now putting out word that it has abandoned an earlier proposal to overhaul rebates.
Basic subscription required
Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.